Skip to content

The cost-effectiveness of one-time birth cohort screening for hepatitis C as part of the NHS health check programme in England

Research output: Contribution to journalArticle

Standard

The cost-effectiveness of one-time birth cohort screening for hepatitis C as part of the NHS health check programme in England. / Williams, Jack ; Miners, Alec; Harris, Ross J; Mendal, Sema; Simmons, Ruth; Ireland, Georgina; Hickman, Matthew; Gore, Charles; Vickerman, Peter.

In: Value in Health, 29.06.2019.

Research output: Contribution to journalArticle

Harvard

Williams, J, Miners, A, Harris, RJ, Mendal, S, Simmons, R, Ireland, G, Hickman, M, Gore, C & Vickerman, P 2019, 'The cost-effectiveness of one-time birth cohort screening for hepatitis C as part of the NHS health check programme in England', Value in Health.

APA

Williams, J., Miners, A., Harris, R. J., Mendal, S., Simmons, R., Ireland, G., ... Vickerman, P. (Accepted/In press). The cost-effectiveness of one-time birth cohort screening for hepatitis C as part of the NHS health check programme in England. Value in Health.

Vancouver

Williams J, Miners A, Harris RJ, Mendal S, Simmons R, Ireland G et al. The cost-effectiveness of one-time birth cohort screening for hepatitis C as part of the NHS health check programme in England. Value in Health. 2019 Jun 29.

Author

Williams, Jack ; Miners, Alec ; Harris, Ross J ; Mendal, Sema ; Simmons, Ruth ; Ireland, Georgina ; Hickman, Matthew ; Gore, Charles ; Vickerman, Peter. / The cost-effectiveness of one-time birth cohort screening for hepatitis C as part of the NHS health check programme in England. In: Value in Health. 2019.

Bibtex

@article{47bac62bc26140c4a2a5e207d97331e3,
title = "The cost-effectiveness of one-time birth cohort screening for hepatitis C as part of the NHS health check programme in England",
abstract = "ObjectivesWe aim to evaluate the cost-effectiveness of one-time HCV screening for individuals born between 1950 and 1979 as part of the NHS health check in England, a health check for adults aged 40-74 years old in primary care.MethodsA Markov model was developed to analyse add-on HCV testing to the NHS health check for individuals in birth cohorts between 1950 and 1979, versus current background HCV testing only, over a lifetime time horizon. The model used data from a back-calculation model of the burden of HCV in England, sentinel surveillance of HCV testing, and published literature. Results are presented from a health service perspective in pounds (GBP) in 2017, as incremental cost-effectiveness ratios (ICERs) per quality adjusted life years (QALY) gained.ResultsBase case ICERs ranged from £7,648 to £24,434, and £18,681 to £46,024, across birth cohorts when considering two sources of HCV transition probabilities. The intervention ismost likely to be cost-effective for those born in the 1970’s, and potentially cost-effective for those born from 1955-1969. The model results were most sensitive to the source of HCV transition probabilities, the probability of referral and receiving treatment, and the HCV prevalence amongst testers. The maximum value of future research across all birth cohorts was £11.3 million at £20,000 per QALY gained.ConclusionsBirth cohort screening is likely to be cost-effective for younger birth cohorts, although considerable uncertainty exists for other birth cohorts. Further studies are warranted to reduce uncertainty in cost-effectiveness and consider the acceptability of the intervention.",
keywords = "Health services, National Health Programs, Mass Screening, Hepatitis C, Cost-Benefit Analysis",
author = "Jack Williams and Alec Miners and Harris, {Ross J} and Sema Mendal and Ruth Simmons and Georgina Ireland and Matthew Hickman and Charles Gore and Peter Vickerman",
year = "2019",
month = "6",
day = "29",
language = "English",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier Inc.",

}

RIS - suitable for import to EndNote

TY - JOUR

T1 - The cost-effectiveness of one-time birth cohort screening for hepatitis C as part of the NHS health check programme in England

AU - Williams, Jack

AU - Miners, Alec

AU - Harris, Ross J

AU - Mendal, Sema

AU - Simmons, Ruth

AU - Ireland, Georgina

AU - Hickman, Matthew

AU - Gore, Charles

AU - Vickerman, Peter

PY - 2019/6/29

Y1 - 2019/6/29

N2 - ObjectivesWe aim to evaluate the cost-effectiveness of one-time HCV screening for individuals born between 1950 and 1979 as part of the NHS health check in England, a health check for adults aged 40-74 years old in primary care.MethodsA Markov model was developed to analyse add-on HCV testing to the NHS health check for individuals in birth cohorts between 1950 and 1979, versus current background HCV testing only, over a lifetime time horizon. The model used data from a back-calculation model of the burden of HCV in England, sentinel surveillance of HCV testing, and published literature. Results are presented from a health service perspective in pounds (GBP) in 2017, as incremental cost-effectiveness ratios (ICERs) per quality adjusted life years (QALY) gained.ResultsBase case ICERs ranged from £7,648 to £24,434, and £18,681 to £46,024, across birth cohorts when considering two sources of HCV transition probabilities. The intervention ismost likely to be cost-effective for those born in the 1970’s, and potentially cost-effective for those born from 1955-1969. The model results were most sensitive to the source of HCV transition probabilities, the probability of referral and receiving treatment, and the HCV prevalence amongst testers. The maximum value of future research across all birth cohorts was £11.3 million at £20,000 per QALY gained.ConclusionsBirth cohort screening is likely to be cost-effective for younger birth cohorts, although considerable uncertainty exists for other birth cohorts. Further studies are warranted to reduce uncertainty in cost-effectiveness and consider the acceptability of the intervention.

AB - ObjectivesWe aim to evaluate the cost-effectiveness of one-time HCV screening for individuals born between 1950 and 1979 as part of the NHS health check in England, a health check for adults aged 40-74 years old in primary care.MethodsA Markov model was developed to analyse add-on HCV testing to the NHS health check for individuals in birth cohorts between 1950 and 1979, versus current background HCV testing only, over a lifetime time horizon. The model used data from a back-calculation model of the burden of HCV in England, sentinel surveillance of HCV testing, and published literature. Results are presented from a health service perspective in pounds (GBP) in 2017, as incremental cost-effectiveness ratios (ICERs) per quality adjusted life years (QALY) gained.ResultsBase case ICERs ranged from £7,648 to £24,434, and £18,681 to £46,024, across birth cohorts when considering two sources of HCV transition probabilities. The intervention ismost likely to be cost-effective for those born in the 1970’s, and potentially cost-effective for those born from 1955-1969. The model results were most sensitive to the source of HCV transition probabilities, the probability of referral and receiving treatment, and the HCV prevalence amongst testers. The maximum value of future research across all birth cohorts was £11.3 million at £20,000 per QALY gained.ConclusionsBirth cohort screening is likely to be cost-effective for younger birth cohorts, although considerable uncertainty exists for other birth cohorts. Further studies are warranted to reduce uncertainty in cost-effectiveness and consider the acceptability of the intervention.

KW - Health services

KW - National Health Programs

KW - Mass Screening

KW - Hepatitis C

KW - Cost-Benefit Analysis

M3 - Article

JO - Value in Health

JF - Value in Health

SN - 1098-3015

ER -